game changer

for PEG & PEGylated drug safety

Our business covers all 3 stages of PEGylated drug…

According to Global Market Insights, the market size for PEGylated drugs in the U.S. exceeded USD 6 billion in 2017 and is projected to reach over USD 8 billion by 2024. While severe acute hypersensitivity and anaphylaxis associated with PEGylated drugs have been well-documented, evidence shows that PEG (polyethylene glycol) itself can also cause anaphylaxis, which cannot be ruled out in PEGylated drugs.

Using our patented FocalTuningTM platform, Leading Life Technologies (LLT) offers products and services for detecting PEG IgE to enhance the safety of PEGylated drugs from pre-clinical to post-marketing stages. Our solutions can benefit both medical research and pharmaceutical professionals, as well as clinical and diagnostic professionals, improving the safety of patients who use PEGylated drugs.



Screening safer PEGylated drug candidates using a human mast cell model. This allows us to evaluate how potential drugs interact with mast cells, which play a role in severe immediate hypersensitivity and anaphylaxis. By developing a better understanding of how PEGylated drugs affect mast cells, we aim to create safer alternatives for biopharmaceutical companies.

clinical trial

Improving PEGylated drug safety with PEG IgE screening. Our patented platform detects vulnerable subjects at risk of severe immediate hypersensitivity and anaphylaxis. By excluding individuals with pre-existing PEG IgE during drug candidate testing, we can create safer treatments for patients and benefit pharmaceutical companies.


Improving post-marketing PEGylated drug safety with PEG IgE screening. Our platform identifies high-risk subjects for anaphylaxis, excluding them from PEGylated drug administration or taking appropriate measures. This approach reduces life-threatening events and benefits patients and the pharmaceutical industry.

Our Tool

Our Work

LLT offers products and services to improve PEGylated drug safety across all stages, from preclinical research to post-marketing surveillance. LLT uses in vitro sensitized human mast cell models to screen and optimize safer PEGylated drug candidates in the preclinical stage. During clinical trials, LLT helps pharmaceutical companies improve the safety of PEGylated drug candidates by identifying and excluding vulnerable subjects with pre-existing PEG IgE using our patented platform. In the post-marketing stage, LLT assists healthcare providers and patients in reducing potential adverse events of life-threatening anaphylaxis and death by screening vulnerable subjects with pre-existing PEG IgE.

FocalTuningTM is a patented universal immunoassay platform that can be tailored and applied in a variety of life science research and diagnostic areas. Our breakthrough application includes monitoring anti-PEG IgE immunogenicity.

Pharmaceutical companies and diagnostic laboratories may consider non-exclusive licensing of our PEG IgE detection technology.

Happy Clients

Our number 1 priority

As a game changer in PEG immunogenicity surveillance, particularly in the detection of PEG IgE, we prioritize and value the support we provide to our customers, clients, and partners who share our pioneering spirit in this field.

We help people and patients by serving happy clients in pharmaceutical and diagnostic companies, as well as research and clinical labs.


Features of  FocalTuning™ platform

  • Removing internal background of each analyte
  • Patented technology
  • Unbeatable accuracy
  • Tiny sample needed (50ul)
  • Super sensitive
  • High specificity


Using next-generation technology, signature products, and top-quality service to improve health and save lives.


Originating from a Stanford researcher in 2012, we are driven by innovation and embracing a brilliant tomorrow.


Founded by scientist and teamed up by professionals. We welcome individuals who share our vision to join us.


Leading Life Technologies is based in the heart of Silicon Valley, California, in the bio-cluster Bay Area.

FocalTuningTM platform

perfect for surveiling PEG immunogenicity